Abstract
Prostate-specific membrane antigen targeting positron emission tomography (PSMA-PET) is nowadays widely used for the management of patients with prostate cancer during natural history of the disease. PSMA is not specific to prostate tissue, many benign and malignant diseases unrelated to prostate cancer are frequently found on PSMA-PET examinations, leading to false positives results and potentially to inadequate patient management. Various interpretation criteria have been proposed within classifications in order to standardize and homogenize PSMA-PET interpretation. This article describes, on the one hand the PSMA-RADS classification, and on the other hand the PROMISE criteria.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
